nimodipine has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nimodipine was ineffective in slowing the progress of ALS." | 6.68 | Controlled trial of nimodipine in amyotrophic lateral sclerosis. ( Dao, H; Graves, J; Khramstov, A; Mendoza, M; Miller, RG; Shepherd, R; Smith, S, 1996) |
| "Nimodipine was ineffective in slowing the progress of ALS." | 2.68 | Controlled trial of nimodipine in amyotrophic lateral sclerosis. ( Dao, H; Graves, J; Khramstov, A; Mendoza, M; Miller, RG; Shepherd, R; Smith, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, A | 1 |
| Liu, C | 1 |
| Ye, W | 2 |
| Huang, D | 1 |
| She, W | 1 |
| Liu, X | 1 |
| Fung, CP | 1 |
| Xu, N | 1 |
| Suen, MC | 1 |
| Sung, HHY | 1 |
| Williams, ID | 1 |
| Zhu, G | 1 |
| Qian, PY | 1 |
| Kriz, J | 1 |
| Gowing, G | 1 |
| Julien, JP | 1 |
| Miller, RG | 1 |
| Shepherd, R | 1 |
| Dao, H | 1 |
| Khramstov, A | 1 |
| Mendoza, M | 1 |
| Graves, J | 1 |
| Smith, S | 1 |
| Apostolski, S | 1 |
| Marinković, Z | 1 |
| Nikolić, A | 1 |
| Blagojević, D | 1 |
| Spasić, MB | 1 |
| Michelson, AM | 1 |
2 trials available for nimodipine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Controlled trial of nimodipine in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Female; Humans; Male; Middle Aged; Nimodipine; P | 1996 |
Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation.
Topics: Adult; Aged; Amino Acids; Amyotrophic Lateral Sclerosis; beta Carotene; Calcium Channel Blockers; Ca | 1998 |
2 other studies available for nimodipine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Selective
Topics: Amyotrophic Lateral Sclerosis; Animals; Biological Products; C9orf72 Protein; DNA; Drosophila; Front | 2022 |
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Axons; Calcium Channel | 2003 |